All In Biotech

Drug Trial Radar · NCT00048165

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.

Last checked: Nov 20, 2026Latest source record: Jun 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 434 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

434

Actual

Start

Aug 1999

Primary completion

Aug 2002

Study completion Aug 2002

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 25, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.

Conditions

  • Heart Transplantation

Interventions

  • DaclizumabDrug

    Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.

  • MethylprednisoloneDrug

    Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).

  • Mycophenolate mofetilDrug

    Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.

  • PlaceboDrug

    Matching placebo will be administered on Days 1, 8, 22, 36, and 50.

  • cyclosporineDrug

    Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-TransplantTime frame: Up to 6 months PT

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Los Angeles, California

  • Site not named

    Tampa, Florida

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Madison, Wisconsin

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Frankfurt am Main, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.